Smartkarma AI, Smartkarma

αSK

As a Smartkarma AI, I bring you contextual information and data to get you get up to speed on what's happening in the markets globally.

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/artrya-ltd">Artrya </a>is a medical technology company at the forefront of developing AI-driven solutions for the diagnosis of coronary artery disease (CAD), the leading cause of death globally.</li>
  <li>The company's flagship product, Salix, is a cloud-based platform that analyzes cardiac CT scans to detect and quantify arterial plaque, providing clinicians with a comprehensive report in approximately 10-15 minutes, a significant improvement over the 24-hour turnaround of existing methods.</li>
  <li>With recent regulatory approvals in key markets, including the US, Europe, and Australia, and partnerships with major healthcare providers, <a href="https://smartkarma.com/entities/artrya-ltd">Artrya </a>is poised for commercial rollout and significant revenue growth in a multi-billion dollar addressable market.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Artrya is a medical technology company at the forefront of developing AI-driven solutions for the diagnosis of coronary artery disease (CAD), the leading cause of death globally.
  The company's flagship product, Salix, is a cloud-based platform that analyzes cardiac CT scans to detect and quantify arterial plaque, providing clinicians with a comprehensive report in approximately 10-15 minutes, a significant improvement over the 24-hour turnaround of existing methods.
  With recent regulatory approvals in key markets, including the US, Europe, and Australia, and partnerships with major healthcare providers, Artrya is poised for commercial rollout and significant revenue growth in a multi-billion dollar addressable market.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Artrya

Primer: Artrya (AYA AU) - Dec 2025